BROCHURE

Cloverleaf unlocks the power of real-world evidence in clinical and pharmaceutical research

Healthcare

The utilization of real-world evidence (RWE) extracted from sources that include electronic health records, claims databases, patient registries, and wearable devices is gaining momentum.

Cloverleaf® the premier clinical interoperability platform, is your gateway to unlock the full potential of RWE in clinical and pharmaceutical research. With thousands of successful implementations worldwide, Cloverleaf facilitates rapid and efficient data connectivity with collaboration partners.

RWE that is incorporated into research brings forth a host of compelling advantages:

- **Broader patient representation**: Clinical trials often impose rigid inclusion and exclusion criteria, restricting the diversity of the patient pool. In contrast, RWE empowers researchers to include a more varied and representative patient group, enriching enrollment diversity while safeguarding the recruitment phase, saving valuable time and resources for sponsors.

> **After in-depth product evaluation, we decided to invest in Infor Cloverleaf, letting us efficiently exchange data to our caregivers and decision makers so they can focus on business priorities that can make the biggest impact on our growth"**
>
> ABHILASH SABARATHINAM
> Head of Integration, Flatiron Health

- **Larger sample sizes**: RWE empowers researchers with vast datasets from large patient populations (potentially thousands or even millions). This substantial sample size provides heightened statistical power and precision when evaluating drug efficacy and safety. The result is a more comprehensive understanding of drug reactions within a broader patient spectrum.
- **Long-term and real-life outcomes**: Conventional clinical trials confine patients to controlled environments for a limited duration, making it challenging to capture real-life scenarios and long-term effects. RWE, however, allows for the observation of patients in their natural settings over extended periods. Offering a more holistic view of drug performance and safety.
- **Cost-effectiveness**: RWE creates a repository of data that can be used throughout the life cycle of a clinical trial. Its potential to replace costly studies and undergo multiple uses streamlines the research process, resulting in a more efficient approach for drug developers, accelerating the time-to-market and potentially saving more lives.
- **Post-marketing surveillance**: RWE plays a pivotal role in post-marketing surveillance, allowing for continuous monitoring of a drug's safety and effectiveness once it enters the general market. An emergence of unusual side effects can be swiftly detected and used to inform regulatory decisions and healthcare practices.
- **Research flexibility and speed**: RWE analysis can be swifter and more adaptable than conducting new clinical trials, and since it can be persisted in a standard data format (HL7 FHIR), it can be re-analyzed and re-used for multiple molecule pipelines. Additionally, RWE can complement traditional clinical trials, enriching the understanding and documentation throughout the approval process.

Talk to us today to learn how Cloverleaf can help you accelerate clinical and pharmaceutical research projects.

Cloverleaf

Cloverleaf seamlessly normalizes data syntactically and structurally into FHIR, a full featured FHIR Server that can persist FHIR objects in a scalable RDBMS, offering optional semantic normalization and pseudonymization services. FHIR data can be securely stored for analysis and mapped into OMOP or CDISC formats to suit your requirements.

This can be delivered as a SaaS fully managed by Infor® or in a preconfigured solution for your own cloud or datacenter deployment.

Cloverleaf core integration engine with enterprise scale security features and global monitor, allows centralized supervision of thousands of connections and interfaces, performing syntactical normalization and format conversion at scale.

Cloverleaf FHIR Bridge provides Infor web services mappings that translate HL7 v2 and CDA input into FHIR at scale and in real time.

Infor Cloverleaf is specifically designed to convert legacy input formats, into FHIR and load it into any data lake and data analytics platform service.

Pre-integrated partner solutions are available to increase data semantic homogeneity to increase analytical value or perform PHI pseudonymization.

Infor API Gateway can expose or receive securely and efficiently FHIR objects to/from APIs. This is ideal to collect data from IOT devices.

LEARN MORE

Follow us:

641 Avenue of the Americas, New York, NY 10011

INF-2946931-en-US-0923-1